About this Journal Submit a Manuscript Table of Contents
Case Reports in Rheumatology
Volume 2012 (2012), Article ID 836930, 3 pages
http://dx.doi.org/10.1155/2012/836930
Case Report

Polymyositis following Pandemic Influenza A (H1N1) and 2009-10 Seasonal Trivalent Vaccines

1Rheumatology Unit, Azienda Policlinico-Universitaria Policlinico di Modena, Via del Pozzo 71, 41124 Modena, Italy
2Rheumatology Unit, Department of Internal Medicine, University of Modena and Reggio Emilia and Azienda Ospedaliero-Universitaria Policlinico di Modena, Via del Pozzo 71, 41124 Modena, Italy
3Critical Care Unit, Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Italy

Received 21 May 2012; Accepted 19 June 2012

Academic Editors: G. S. Alarcon, H. Alexanderson, J. C. Nossent, and M. Salazar-Paramo

Copyright © 2012 Clodoveo Ferri et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Black, J. Eskola, C. A. Siegrist et al., “Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines,” The Lancet, vol. 374, no. 9707, pp. 2115–2122, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. Centers for Disease Control and Prevention (CDC), “Safety of influenza A, (H1N1) 2009 monovalent vaccines—United States, October 1-November 24, 2009,” Morbidity and Mortality Weekly Report, vol. 58, pp. 1351–1356, 2009.
  3. E. Plennevaux, E. Sheldon, M. Blatter, M. K. Reeves-Hoché, and M. Denis, “Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials,” The Lancet, vol. 375, no. 9708, pp. 41–48, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. X. F. Liang, L. Li, D. W. Liu, et al., “Safety of influenza A, (H1N1) vaccine in postmarketing surveillance in China,” The New England Journal of Medicine, vol. 364, no. 7, pp. 638–647, 2011.
  5. Z. Vajo, F. Tamas, L. Sinka, and I. Jankovics, “Safety and immunogenicity of a 2009 pandemic influenza A H1N1 vaccine when administered alone or simultaneously with the seasonal influenza vaccine for the 2009-10 influenza season: a multicentre, randomised controlled trial,” The Lancet, vol. 375, no. 9708, pp. 49–55, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. F. L. Mastaglia and B. A. Phillips, “Idiopathic inflammatory myopathies: epidemiology, classification, and diagnostic criteria,” Rheumatic Disease Clinics of North America, vol. 28, no. 4, pp. 723–741, 2002. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Gaubitz, “Epidemiology of connective tissue disorders,” Rheumatology, vol. 45, no. 3, pp. iii3–iii4, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. F. M. Jani, J. P. Gray, and J. Lanham, “Influenza vaccine and dermatomyositis,” Vaccine, vol. 12, no. 15, article 1484, 1994. View at Scopus
  9. H. Orbach and A. Tanay, “Vaccines as a trigger for myopathies,” Lupus, vol. 18, no. 13, pp. 1213–1216, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. M. C. Dalakas, “Pathophysiology of inflammatory and autoimmune myopathies,” Presse Medicale, vol. 40, no. 4, pp. e237–e247, 2011. View at Publisher · View at Google Scholar · View at Scopus